Understanding how specific genes affect pancreatic cancer
Official title: Investigating the role of FOXA1/2 and HNF4⍺ in Pancreatic ductal adenocarcinoma
Funded at University of Utah · NIH-10903161 · Data updated 2026-11-12
This study is looking at how certain proteins affect a type of aggressive pancreatic cancer called PDAC, to help find better ways to treat patients and improve their outcomes.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $42,250 |
| NIH project number | 1F31CA291031-01 |
| Project ID | NIH-10903161 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those with the classical subtype.
✕Less likely to help
Patients with other forms of pancreatic cancer or those who do not have pancreatic cancer may not benefit from this research.
What this research studies
This research investigates the role of specific transcription factors, FOXA1, FOXA2, and HNF4⍺, in pancreatic ductal adenocarcinoma (PDAC), a highly aggressive form of cancer. By analyzing the differences between two subtypes of PDAC, the classical and basal, the study aims to uncover how these factors influence tumor behavior and patient responses to treatment. The research employs integrated genomic, transcriptomic, and proteomic analyses to identify potential biomarkers and therapeutic targets that could improve patient outcomes. Ultimately, the goal is to enhance understanding of the disease and develop more effective treatments for patients diagnosed with PDAC.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that significantly improve survival rates for patients with pancreatic cancer.
How similar studies have gone: Previous research has shown promise in targeting specific transcription factors in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
-
University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Orellana, Walter Alexander — University of Utah
- Study coordinator: Orellana, Walter Alexander
Related research
Other NIH-funded projects on the same topics.
-
Fibrin-rich tumor stroma as a new driver of immune response in pancreatic cancer
This grant explores how fibrin-involved tumor surroundings in pancreatic cancer might affect immune therapy, with the goal of making treatments work better for patients.
-
TREM2+ macrophages and liver metastases in pancreatic cancer
Researchers are studying immune cells in liver metastases from pancreatic cancer to understand how they influence the cancer’s spread and more effective treatments.
-
Protein S could slow pancreatic cancer and blood clots
A potential treatment study looks at restoring a natural blood protein, Protein S, to help people with pancreatic cancer by slowing tumor growth and reducing dangerous clots.
-
In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
-
Metabolic changes in pancreatic cancer when treated with crisantaspase
Aims to understand how pancreatic cancer cells adapt their metabolism when treated with crisantaspase to inform better treatment strategies for patients.
-
New combination therapy for pancreatic cancer in animals
A new therapy designed to weaken the tumor’s protective surroundings and boost treatment effects in pancreatic cancer models.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.